Regeneron Pharmaceuticals REGN
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 81st percentile, 5-year average 18.3x
#1770 of 2972 stocks by PE (1 = cheapest)
Below its usual level · 39th percentile, 5-year average 3.2x
#3724 of 5311 stocks by PB (1 = cheapest)
Around its usual level · 53rd percentile, 5-year average 5.9x
#4033 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.01 | – | 3.24 | 39% (cheaper than usual) | #3724 of 5311 (1 = cheapest) |
| PE | 22.96 | 12.07 | 18.26 | 81% (pricier than usual) | #1770 of 2972 (1 = cheapest) |
| PS | 5.65 | 4.60 | 5.90 | 53% (pricier than usual) | #4033 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on REGN.
Sign in to join the discussion.